Skip to content
The Kids Research Institute Australia logo
Donate

Search

2017 Update for the Vaccine Trials Group

Wrap up of the people, projects and updates from 2017 in the Vaccine Trials Group research area, and Dr Peter Richmond.

Other VTG studies

Contact us If you'd like to get in touch, please contact us by phone or email. Phone: 0400 450 240 Email: vtg@thekids.org.au Clostridium difficile

Meningococcal studies

Contact us If you'd like to get in touch, please contact us by phone or email. Phone: 0400 450 240 Email: vtg@thekids.org.au Meningococcus (Neisseria

Respiratory Syncytial Virus (RSV) studies

Contact us If you'd like to get in touch, please contact us by phone or email. Phone: 0400 450 240 Email: vtg@thekids.org.au Respiratory Syncytial

Surveillance studies

Contact us If you'd like to get in touch, please contact us by phone or email. Phone: 0400 450 240 Email: vtg@thekids.org.au Paediatric Active

Celebrating 10 Years of the Wesfarmers Centre

A decade long partnership with Wesfarmers Ltd. and the Wesfarmers Centre of Vaccines and Infectious Diseases has led to world-class paediatric research and important collaborations fuelling the Centre’s trajectory towards easing the burden of infectious diseases.

Meningococcal disease

Meningococcal disease is caused by the bacteria Neisseria meningitidis, or 'meningococcus'. It's an uncommon but very serious disease that can result in death.

Screening and Management Practices for Polyoma (BK) Viremia and Nephropathy in Kidney Transplant Recipients From the Lands Down Under: Addressing the Unknowns and Rationale for a Multicenter Clinical Trial

BK polyomavirus infection in transplanted kidneys that leads to BK virus–associated nephropathy (BKVAN) is an important cause of allograft loss and has limited treatment options. Recent data suggest that BK viremia affects approximately 10% of people within the first 12 months following kidney transplantation. Among recipients with BKVAN, the overall risk of allograft loss is substantially increased, estimated to be 50% within 5 years of diagnosis.

New pneumococcal vaccine closes in on approval

Pneumococcal – a bacterial infection that can cause pneumonia and meningitis – is responsible for 1000s of hospital admissions in Australia each year, many of them children.